J-Pharma
520A.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Operating income | −¥3.7bn | −¥1.6bn | — | — | — |
| Ordinary income | −¥2.6bn | −¥1.5bn | −¥1.6bn | −¥1.1bn | −¥1.1bn |
| Total assets | ¥4.8bn | ¥2.9bn | ¥1.2bn | ¥1.8bn | ¥1.2bn |
| Net assets / equity | ¥4.4bn | ¥2.4bn | ¥950m | ¥1.4bn | ¥994m |
| Operating cash flow | −¥2.2bn | −¥1.7bn | −¥1.4bn | — | — |
| EPS (basic) | ¥-195.08 | ¥-184.05 | ¥-263.57 | ¥-952.74 | ¥-974.48 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 92 figures · EDINET |